TAGRISSO™▼ (osimertinib)
TAGRISSO is an EGFR TKI indicated as a monotherapy for:
First-line TAGRISSO
Efficacy
Overall survival
First-line TAGRISSO: The only treatment with median overall survival beyond 3 years1,4
In the FLAURA study progression free survival was the primary endpoint. Overall survival was a secondary endpoint
In a global Phase III study of advanced EGFRm NSCLC4
Statistically significant overall survival
Nearly 30% of patients were still being treated with first-line TAGRISSO at 3 years4
Duration of therapy
PFS
In the FLAURA trial, 1L TAGRISSO met its primary endpoint and delivered an unprecedented median PFS of 18.9 months versus 10.2 months in the first-generation TKIs gefitinib and erlotinib.2
Kaplan-Meier estimates of the duration of PFS by investigator assessment 2*
CNS efficacy
1L TAGRISSO reduced the risk of CNS progression by 52% (HR 0.48 (95% CI 0.26-0.86) p=0.014) (nominally significant) versus first-generation EGFR TKIs.5
Overall response rate
The ORR with 1L TAGRISSO was similar to first-generation EGFR TKIs:2
PFS per blinded independent central review (BICR) in patients with CNS metastases at baseline:2
Duration of response
1L TAGRISSO more than doubled median duration of response duration of response versus first-generation EGFR TKIs.2
